Survival of European children and young adults with cancer diagnosed 1995–2002
Introduction
About 15,000 children (age 0–14 years) and 20,000 adolescents/young adults (age 15–24 years) are diagnosed with cancer each year in Europe.1 Although only 1% of all cancers are diagnosed in these age groups, they have a number of characteristics that increase their impact on society:
- –
The prevalence of adults diagnosed with cancer before age 25 is increasing due to improving survival, and to a lesser extent, increasing cancer incidence.2
- –
The risk of second cancers is high in adults surviving cancer diagnosed before age 25.
- –
Many cancer survivors diagnosed before age 25 experience sequelae in later life that require medical treatment.
- –
European populations differ markedly in cancer survival, implying inequality of access to treatment for diseases in young people which are typically highly curable.
- –
Survival in adolescents/young adults is worse than in children with biologically similar cancers, probably because intensive treatment protocols have been mainly developed for children.
Survival data for young Europeans (below age 25) diagnosed with cancer between 1978 and 1994 are available in various EUROCARE publications.3, 4 The ACCIS project5 produced survival figures for European children and adolescents <20 up to diagnosis year 1997, and substantiated the disparities in survival across Europe brought to light by EUROCARE. The present EUROCARE-4 study analyses survival and survival time trends in young Europeans diagnosed with cancer between 1995 and 2002, and also examines trends in survival differences between different European populations.
Section snippets
Materials and methods
Survival was analysed for 40,392 European children (age 0–14 years) and 30,187 adolescents/young adults (age 15–24 years) diagnosed with cancer during the period 1995–2002 and followed-up at least until December 31, 2003. All cases with a malignant neoplasm, as defined by ICD for Oncology (ICD-O-3)6 behaviour code 3 or higher, were included. Only first tumours were analysed; 771 cases were excluded from the analysis as they were second or later primary tumours.
The cases were contributed by 83
All cancers combined
Five-year survival estimates by country for all cancers combined diagnosed in 1995–2002 are shown in Fig. 1 (children) and Fig. 2 (adolescents/young adults). For most countries survival in children ranged between 78% and 83%. Malta and Czech Republic had lower survival (75% and 76%, respectively), which did not, however, differ significantly from mean European survival (81%). Austria had the highest survival (86%). For adolescents/young adults, 5-year survival was 87% overall, and the range was
Discussion
The two major – and encouraging – findings of our study are that survival for all cancers combined improved significantly across Europe (more for adolescents/young adults than for children) and that the survival gap between countries reduced. Considering individual cancers, survival increased significantly for leukaemias and PNET in children, and for non-Hodgkin lymphoma in adolescents/young adults.
For all cancers combined, notable increases in survival were achieved by countries with poor
Conflict of interest statement
None declared.
EUROCARE-4 Working Group
Austria: W Oberaigner (Tyrol Cancer Registry); M Hackl (Austrian National Cancer Registry); Belgium: E Van Eycken; Martine Verstreken (Flemish Cancer Registry), Czech Republic: J Holub, L Jurickova (West Bohemia Cancer Registry); Denmark: HH Storm; G Engholm (Danish Cancer Society, Dept. Cancer Prevention & Documentation); Finland: T Hakulinen (Finnish Cancer Registry); France: A Belot (FRANCIM); G Hédelin, M Velten (Bas-Rhin Cancer Registry); I Tron, E Le Gall (Bretagne Childhood Cancer
Acknowledgements
We thank Don Ward for help with the English and Samba Sowe for editorial support. The research was supported by the Compagnia di San Paolo, Torino, Italy. The Spanish RNTI-SEHOP is in the ISCIII-RTICC RD06/0020 and receives partial support from the Scientific Foundation of the Asociación Española Contra el Cáncer and the Fundación Villavecchia.
References (22)
- et al.
Time trends of cancer incidence in European children (1978–1997): report from the ACCIS project
Eur J Cancer
(2006) - et al.
Childhood cancer survival in Europe 1978–1992: the EUROCARE study
Eur J Cancer
(2001) - et al.
Cancer survival in European adolescents and young adults
Eur J Cancer
(2003) - et al.
Geographical comparison of cancer survival in Europe children children (1978–1997): report from the ACCIS project
Eur J Cancer
(2006) - et al.
A computer program package for relative survival analysis
Comput Prog Biomed
(1985) - et al.
The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis
Eur J Cancer
(2009) - et al.
Cancer in children and adolescents in Europe: developments over 20 years and future challenges
Eur J Cancer
(2006) Keynote comment: challenges of teenage and young-adult oncology
Lancet Oncol
(2006)- et al.
The challenge of very rare tumours in childhood: the Italian TREP project
Eur J Cancer
(2007) - et al.
Guidelines for surgical treatment of hepatoblastoma in the modern era-recommendations from the childhood liver tumour strategy group of the international society of paediatric oncology (SIOPEL)
Eur J Cancer
(2005)
Cited by (431)
Survival of European adolescents and young adults diagnosed with cancer in 2010–2014
2024, European Journal of CancerCharacteristics of radiotherapy for adolescents and young adults
2023, Cancer/RadiotherapieImpact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents
2023, The Lancet Child and Adolescent HealthCancer burden in adolescents and young adults in Europe
2023, ESMO OpenThe Prognostic Role of Chronic Obstructive Pulmonary Disease for Lung Cancer After Pulmonary Resection
2022, Journal of Surgical Research